Potential predictive angiogenic markers, such as immunohistochemistry of CD31, TSP-1, VEGF, p53, and ELISA, of circulating levels of VEGF were prospectively examined in the GOG phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer, but none had been validated [83]. This evidence concerns the gene VEGFA and peritoneum cancer.